PPHM – Trade Note #1
Note: Patrick believes there is a risk this trades below $1 prior to OCT expiration if the company comes back with the analysis of what happened or the OS data from the 1st line trial is negative (which he expects) prior to that time.
ACHN – Trade Note #1
Note: Company has an R&D day on Sept 27th and AASLD in early November — both which may increase volatility.
ASTX – Trade Note #1
Research Link: https://www.chimeraresearchgroup.com/2012/09/upcoming-events-for-nktr-astx-thld/
ONCY – Phase III Trade Strategy
Some comments from Patrick on this name: When to expect the data: Oncolytics Biotech is running a two-stage Phase III clinical trial examining REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers (REO 018). From the company’s June 20th DMC safety review, “The study design stipulates that the study […]
